...
首页> 外文期刊>Research in social & administrative pharmacy: RSAP >Media coverage of off-label promotion: a content analysis of US newspapers.
【24h】

Media coverage of off-label promotion: a content analysis of US newspapers.

机译:标签外促销的媒体报道:对美国报纸的内容分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Promotion of drugs for off-label use is newsworthy, because it is an illegal but all too common strategy used by pharmaceutical companies. The print media are an important source of information about coverage of off-label promotion of drugs and devices and can influence public perceptions of the practice. OBJECTIVES: Print media coverage of off-label promotion during the years 1990-2008 were described and quantified. The primary themes and general tones relating to off-label promotion articles were evaluated. General concerns associated with off-label promotion and complaints about specific brand name drugs were also identified. METHODS: Content analyses of the top 6 US newspapers were conducted over the period of 1990-2008 to analyze the media coverage given to off-label promotion of drugs and devices. Headlines and full text of articles were analyzed for primary themes and tones of the coverage. Intercoder reliability tests were performed on all the study variables. RESULTS: One hundred and one articles were identified meeting the study inclusion criteria. Coverage varied by newspaper. The Wall Street Journal had the most coverage on the topic (45%), and USA Today and Chicago Tribune had the least coverage (5%). Overall, most of the stories sampled were deemed to have a negative tone in coverage (77%), focusing mainly on lawsuits against drug companies for promoting their drugs for off-label uses. Pfizer's Neurontin((R)) (Pfizer Inc., New York, NY 10017, USA) and Johnson & Johnson's Retin-A((R)) (Orthoneutrogena, Los Angeles, CA 90045, USA) received the most media attention. CONCLUSION: The news media helps shape public understanding of promotional practices of pharmaceutical companies and their potential benefits and harms. This study suggests that print media coverage is generally negative about off-label promotion, focusing on legal actions taken against drug companies and the negative consequences of such promotional practices.
机译:背景:宣传用于非标签使用的药物具有新闻价值,因为这是制药公司所使用的非法策略,但过于普遍。印刷媒体是有关标签和药品促销的重要信息来源,并且可以影响公众对该做法的看法。目的:描述和量化1990-2008年间标签外促销的印刷媒体报道。评估了与标签外促销商品有关的主要主题和一般色调。还确定了与标签外促销有关的一般问题以及对特定品牌药的投诉。方法:在1990年至2008年期间,对美国排名前6位的报纸进行了内容分析,以分析媒体对不合规定的药品和器械促销的报道。分析了文章的标题和全文,以了解报道的主要主题和基调。对所有研究变量进行了编码器间可靠性测试。结果:确定了101篇符合研究纳入标准的文章。报道范围因报纸而异。 《华尔街日报》对此主题的报道最多(45%),《今日美国》和《芝加哥论坛报》的报道最少(5%)。总体而言,被抽样的大多数故事被认为覆盖率较低(77%),主要集中在针对药品公司宣传其标签外药品的诉讼。辉瑞公司的Neurontin(R)(辉瑞公司,纽约,NY 10017,美国)和强生公司的Retin-A(R)(Orthoneutrogena,洛杉矶,CA 90045,美国)受到了最多的媒体关注。结论:新闻媒体有助于塑造公众对制药公司促销活动及其潜在利弊的理解。这项研究表明,印刷媒体的报道通常对标签外促销不利,重点是针对药品公司采取的法律行动以及此类促销做法的不利后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号